Pharmaceutical drug discovery is undergoing such rapid innovation that therapeutic breakthroughs that could only once be imagined are now commonplace in research labs around the world.
With this remarkable success comes further aspiration for the discovery of many more therapeutic pathways and effective new medicines to give fresh hope to patients. But what challenges will we need to overcome to continue to move forward – and what can we hope to achieve in the future? All this and more will be revealed at ELRIG’s Drug Discovery 2018 conference – so make sure you don’t miss out and sign up now to keep up-to-date with future announcements!
To get an initial glimpse into what the future might hold, we’ve enlisted the help of Melanie Leveridge, Head of Screening, Profiling and Mechanistic Biology at GlaxoSmithKline, UK. Below Mel shares her professional insights into what she thinks will shape the future of drug discovery, including the importance of reducing drug candidate attrition, encouraging collaboration, and adopting novel technologies to drive research success.